'Sonablate HIFU enables very precise prostate tissue ablation with minimal effect on important nearby structures.' - Dr. Tracy Gapin
Charlotte, NC (PRWEB) December 17, 2015
SonaCare Medical, LLC, industry leader in minimally invasive high intensity focused ultrasound (HIFU) technologies, is pleased to report that Dr. Tracy Gapin has begun delivering prostate ablations at the Sarasota Interventional Radiology Treatment Center (SIR). Dr. Gapin performed his first U.S. Sonablate® procedure at SIR earlier this week, on December 15th, with guidance from Stephen Scionti, MD.
Prior to Sonablate’s FDA clearance, Dr. Gapin performed Sonablate procedures outside of the United States at International HIFU treatment centers. He has been actively participating in the Sonablate HIFU community for over three years and has attended ‘Center of Excellence’ educational programs focused on the advancement of HIFU. Dr. Gapin’s decision to launch a HIFU program at the Sarasota Interventional Radiology Treatment Center shows his continued support for HIFU as well as his persistent confidence in Sonablate as a preferred option for prostate tissue ablation. “My patients are very concerned with preserving quality of life including normal sexual and urinary function,” states Dr. Tracy Gapin. “Sonablate HIFU enables very precise prostate tissue ablation with minimal effect on important nearby structures. This enables excellent outcomes with minimal side effects such as urinary incontinence and erectile dysfunction. Men really appreciate the ability to quickly return to their normal life after HIFU treatment and I am excited to be able to offer patients such an option.”
As an expert in the field of this innovative technology, Dr. Stephen Scionti is now providing training for physicians through case observations, thereby giving potential new users an opportunity to gain exposure to HIFU. Dr. Mark Carol, CEO of SonaCare Medical, states, "We are delighted that Dr. Gapin, a long standing supporter and user of Sonablate, is beginning to provide ablative services at SIR. SonaCare Medical continues to be encouraged by the acceptance and progression of HIFU for the ablation of prostate tissue in the United States, and we are pleased to see the initiative of urologists, like Dr. Scionti, who launch training programs that bring the knowledge of this technology to increasing numbers of physicians across the U.S."
Sonablate® is the first device to receive regulatory authorization from the FDA for the focused ultrasound ablation of prostate tissue. Since its introduction over 15 years ago, Sonablate® technology has been used around the world on nearly 15,000 patients in over 30 countries, including approximately 4,000 U.S. men who have had this procedure performed outside the U.S.
About SonaCare Medical, LLC
SonaCare Medical is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following: Sonablate®, which has 510(K) clearance in the U.S. under a De Novo regulatory classification; Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 49 countries outside the U.S.; Sonatherm® laparoscopic HIFU surgical ablation system, which has 510(K) clearance in the U.S., has CE Marking and has obtained regulatory authorization in more than 30 countries outside the U.S.
For additional information, visit http://www.SonaCareMedical.com
SonaCare Medical, LLC
Erica Griffith (704) 936-1834, EricaGriffith(at)SonaCareMedical(dot)com
Forward Looking Statements.
The Company's forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or other factors.